Unsere Publikationen

Jiang T, Ziemssen T, Wray S, Shen C, Söderbärg K, Lewin JB, Božin I, Freedman MS. Matching-Adjusted Indirect Comparisons of Diroximel Fumarate, Ponesimod, and Teriflunomide for Relapsing Multiple Sclerosis. CNS Drugs. 2023 May 8. PMID: 37155132.
Link
https://doi.org/10.1007/s40263-023-01002-x
Tags
Multiple SkleroseMS Behandlung
Jahr
2023
Zum Eintrag
Dayan CM, Lecumberri B, Muller I, et al. Endocrine and multiple sclerosis outcomes in patients with autoimmune thyroid events in the alemtuzumab CARE-MS studies. Multiple Sclerosis Journal - Experimental, Translational and Clinical. 2023;9(1).
Link
https://doi.org/10.1177/20552173221142741
Tags
Multiple SkleroseMS Behandlung
Jahr
2023
Zum Eintrag
Callegari I, Schneider M, Aebischer V, Voortman MM, Proschmann U, Ziemssen T, Lindberg R, Fischer-Barnicol B, Khalil M, Kappos L, Kuhle J, Sanderson NSR, Derfuss T. Natalizumab in cerebrospinal fluid and breastmilk of patients with multiple sclerosis. Ther Adv Neurol Disord. 2023 Jan 30;16:17562864221150040.
Link
https://doi.org/10.1177/17562864221150040
Tags
Multiple SkleroseMS Behandlung
Jahr
2023
Zum Eintrag
Shinoda K, Li R, Rezk A, Mexhitaj I, Patterson KR, Kakara M, Zuroff L, Bennett JL, von Büdingen HC, Carruthers R, Edwards KR, Fallis R, Giacomini PS, Greenberg BM, Hafler DA, Ionete C, Kaunzner UW, Lock CB, Longbrake EE, Pardo G, Piehl F, Weber MS, Ziemssen T, Jacobs D, Gelfand JM, Cross AH, Cameron B, Musch B, Winger RC, Jia X, Harp CT, Herman A, ...
Link
https://doi.org/10.1073/pnas.2207291120
Tags
Multiple SkleroseMS BehandlungNeuroimmunologie
Jahr
2023
Zum Eintrag
Ziemssen T, Groth M, Ettle B, Bopp T. Immune Response to SARS-CoV-2 mRNA Vaccines in an Open-Label Multicenter Study in Participants with Relapsing Multiple Sclerosis Treated with Ofatumumab. Vaccines (Basel). 2022 Dec 16;10(12):2167.
Link
https://doi.org/10.3390/vaccines10122167
Tags
Multiple SkleroseMS Behandlung
Jahr
2022
Zum Eintrag
Inojosa H, Proschmann U, Akgün K, Ziemssen T. The need for a strategic therapeutic approach: multiple sclerosis in check. Ther Adv Chronic Dis 2022;13.
Link
https://doi.org/10.1177/20406223211063032
Tags
Multiple SkleroseMS Behandlung
Jahr
2022
Zum Eintrag
Koeditz D, Frensch J, Bierbaum M, Ness N-, Ettle B, Vudumula U, et al. Comparing the long-term clinical and economic impact of ofatumumab versus dimethyl fumarate and glatiramer acetate in patients with relapsing multiple sclerosis: A cost-consequence analysis from a societal perspective in Germany. Mult Scler J Exp Transl Clin 2022;8(1).
Link
https://doi.org/10.1177/20552173221085741
Tags
Multiple SkleroseMS Behandlung
Jahr
2022
Zum Eintrag
Constantinescu V, Akgün K, Ziemssen T. Current status and new developments in sphingosine-1-phosphate receptor antagonism: fingolimod and more. Expert Opin Drug Metab Toxicol 2022;18(10):675-693.
Link
https://doi.org/10.1080/17425255.2022.2138330
Tags
Multiple SkleroseMS Behandlung
Jahr
2022
Zum Eintrag

Publikationen durchsuchen

Publikationen filtern

Filter
Tags
Multiple Sklerose
MS Behandlung
Mobilität
Autonomes Nervensystem & Neuroendokrinologie
Neuroimmunologie
Herzratenvariabilität
Baroreflexsensitivität
Management & Science
eHealth
Gesundheitsökonomie
Andere
Zeige alleVerstecke
Jahr
-